XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives
of this study are
- To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in
real world settings, and
- To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT)
initiative. This initiative is designed to evaluate the composite of all death,
myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free
from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and
that have been treated with drug eluting stents (DES) and extended dual antiplatelet
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Abbott Medical Devices Abbott Vascular
Collaborators:
Baim Institute for Clinical Research Bristol-Myers Squibb Daiichi Sankyo Inc. Daiichi Sankyo, Inc. Eli Lilly and Company Harvard Clinical Research Institute